UNSPSC 51283606: Rifamycin amp

This classification denotes an antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-, but more generally known as rifamycin amp, which bears US NIH Compound Identifier 5381226. European Medicines Agency schedules rifamycin amp or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG.

Most nations, for tariff purposes, schedule rifamycin amp under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(C2O)C(C3O)C=NN5CCN(CC5)C)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283606 Rifamycin amp is a Commodity code that nominally covers rifamycin ampules, but recent state and local solicitations tagged under this code diverge significantly from the antibiotic scope. The most active recent procurement under the code is for emergency medical supplies, naloxone products, and pharmaceutical procurement services rather than rifamycin-specific products. Issuing bodies include county health departments, city fire and rescue divisions, state health and human services agencies, and multistate cooperative purchasing alliances. Work being solicited ranges from emergency responder medical and first aid supplies inventories to direct-to-manufacturer pharmaceutical contracting programs and generic multi-source pharmaceutical supply agreements. The code shows mixed activity across state and local jurisdictions with no clear concentration of rifamycin-specific procurement.

Recent representative opportunities include the City of Tampa Fire Department Rescue Division's IFB for 169 line items of medical and emergency response supplies (sealed bid due March 13, 2026, with estimated contract value of $700,000, designated as a sheltered market procurement for certified Small Local Business Enterprises with a 5 percent bid discount capped at $10,000), Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities across Minnesota and Oregon (proposals due March 26, 2026, with contract effective July 1, 2026). Geographic activity spans Florida, Texas, Minnesota, and Oregon. The code shows little relevant recent activity specifically targeting rifamycin products; procurement activity instead centers on broader emergency medical supply categories, naloxone distribution, and pharmaceutical supply-chain management.